Publicaciones en colaboración con investigadores/as de University of Edinburgh (54)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266

2023

  1. An International Expert Delphi Consensus on Defining Textbook Outcome in Liver Surgery (TOLS)

    Annals of Surgery, Vol. 277, Núm. 5, pp. 821-828

  2. EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy

    European Journal of Cancer, Vol. 181, pp. 79-91

  3. Intratumoral injection of IL-12-encoding mRNA targeted to CSFR1 and PD-L1 exerts potent anti-tumor effects without substantial systemic exposure

    Molecular Therapy - Nucleic Acids, Vol. 33, pp. 599-616

  4. Overall Survival with Maintenance Olaparib at a 7-Year Follow-Up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 3, pp. 609-617

  5. Overall Survival with Maintenance Olaparib at a 7-Year Follow-up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

    Obstetrical and Gynecological Survey

  6. Palliative care integration indicators: an European regional analysis

    BMJ Supportive and Palliative Care

  7. Small-bowel capsule endoscopy in patients with Meckel's diverticulum: clinical features, diagnostic workup, and findings. A European multicenter I-CARE study

    Gastrointestinal Endoscopy, Vol. 97, Núm. 5, pp. 917-926.e3

  8. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

    Annals of Oncology

2022

  1. A human IgE bispecific antibody shows potent cytotoxic capacity mediated by monocytes

    Journal of Biological Chemistry, Vol. 298, Núm. 8

  2. Activation of the unfolded protein response (Upr) is associated with cholangiocellular injury, fibrosis and carcinogenesis in an experimental model of fibropolycystic liver disease

    Cancers, Vol. 14, Núm. 1

  3. Advances in mRNA-based drug discovery in cancer immunotherapy

    Expert Opinion on Drug Discovery, Vol. 17, Núm. 1, pp. 41-53

  4. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions

    Gut, Vol. 71, Núm. 8, pp. 1669-1683

  5. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

    The Lancet Oncology, Vol. 23, Núm. 8, pp. e374-e384

  6. Genetic and pharmacological inhibition of XBP1 protects against APAP hepatotoxicity through the activation of autophagy

    Cell death & disease, Vol. 13, Núm. 2, pp. 143

  7. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

  8. Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures

    Gut, Vol. 71, Núm. 6, pp. 1141-1151

  9. Opportunities and challenges of bi-specific antibodies

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 45-70

  10. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268